8 Result(s)

Article

Use of days alive without life support and similar count outcomes in randomised clinical trials – an overview and comparison of methodological choices and analysis methods

Days alive without life support (DAWOLS) and similar outcomes that seek to summarise mortality and non-mortality experiences are increasingly used in critical care research. The use of these outcomes is challe...

Anders Granholm, Benjamin Skov Kaas-Hansen, Theis Lange… in BMC Medical Research Methodology (2023)

Article

Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia

The currently recommended dose of dexamethasone for patients with severe or critical COVID-19 is 6 mg per day (mg/d) regardless of patient features and variation. However, patients with severe or critical COVI...

Bryan S. Blette, Anders Granholm, Fan Li, Manu Shankar-Hari… in Scientific Reports (2023)

Article

Effects of 12 mg vs. 6 mg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial

Thromboembolism is more common in patients with critical COVID-19 than in other critically ill patients, and inflammation has been proposed as a possible mechanism. The aim of this study was to investigate if ...

Sandra Jonmarker, Felix Alarcón, Jacob Litorell… in Annals of Intensive Care (2023)

Article

Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia

We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia.

Anders Granholm, Maj-Brit Nørregaard Kjær, Marie Warrer Munch… in Intensive Care Medicine (2022)

Article

Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial

We compared dexamethasone 12 versus 6 mg daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia in the international, randomised, blinded COVID STEROID 2 trial. In t...

Anders Granholm, Marie Warrer Munch, Sheila Nainan Myatra… in Intensive Care Medicine (2022)

Article

Time for tocilizumab in COVID-19?

Ethan Butler, Marie Warrer Munch, Balasubramanian Venkatesh in Intensive Care Medicine (2021)

Article

Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis

Corticosteroids are now recommended for patients with severe COVID-19 including those with COVID-related ARDS. This has generated renewed interest regarding whether corticosteroids should be used in non-COVID ...

Dipayan Chaudhuri, Kiyoka Sasaki, Aram Karkar, Sameer Sharif… in Intensive Care Medicine (2021)